- Home
- OMER vs WRN Comparison
OMER vs WRN Comparison
Compare OMER & WRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- WRN
- Stock Information
- Founded
- OMER 1994
- WRN 2006
- Country
- OMER United States
- WRN Canada
- Employees
- OMER N/A
- WRN N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- WRN Metal Mining
- Sector
- OMER Health Care
- WRN Basic Materials
- Exchange
- OMER Nasdaq
- WRN Nasdaq
- Market Cap
- OMER 513.8M
- WRN 435.6M
- IPO Year
- OMER 2009
- WRN N/A
- Fundamental
- Price
- OMER $8.83
- WRN $2.10
- Analyst Decision
- OMER Strong Buy
- WRN Strong Buy
- Analyst Count
- OMER 5
- WRN 2
- Target Price
- OMER $27.50
- WRN $4.13
- AVG Volume (30 Days)
- OMER 1.7M
- WRN 1.0M
- Earning Date
- OMER 11-13-2025
- WRN 11-05-2025
- Dividend Yield
- OMER N/A
- WRN N/A
- EPS Growth
- OMER N/A
- WRN N/A
- EPS
- OMER N/A
- WRN N/A
- Revenue
- OMER N/A
- WRN N/A
- Revenue This Year
- OMER N/A
- WRN N/A
- Revenue Next Year
- OMER N/A
- WRN N/A
- P/E Ratio
- OMER N/A
- WRN N/A
- Revenue Growth
- OMER N/A
- WRN N/A
- 52 Week Low
- OMER $2.95
- WRN $0.90
- 52 Week High
- OMER $13.60
- WRN $2.56
- Technical
- Relative Strength Index (RSI)
- OMER 67.40
- WRN 52.06
- Support Level
- OMER $6.24
- WRN $1.96
- Resistance Level
- OMER $7.06
- WRN $2.18
- Average True Range (ATR)
- OMER 0.54
- WRN 0.10
- MACD
- OMER 0.02
- WRN -0.00
- Stochastic Oscillator
- OMER 99.65
- WRN 67.69
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).